Introduction {#section1-1076029619880008}
============

Hospitalized acutely ill medical patients have an increased risk of venous thromboembolism (VTE) including deep vein thrombosis and pulmonary embolism, leading to substantial morbidity and mortality.^[@bibr1-1076029619880008]^ The guideline recommends standard duration thromboprophylaxis up to 21 days, but it is usually terminated at the time of discharge.^[@bibr2-1076029619880008]^ However, despite the administration of standard duration thromboprophylaxis, some acutely ill medical patients with specific risk factors remain at high risk for VTE that extends for at least 5 to 6 weeks following hospital admission. Furthermore, the majority of VTE now occur postdischarge.^[@bibr3-1076029619880008][@bibr4-1076029619880008]--[@bibr5-1076029619880008]^

Previous trials with extended thromboprophylaxis, using different anticoagulant drugs showed some promise in reducing VTE burden but failed to achieve a net clinical benefit because of an increase in major bleeding.^[@bibr2-1076029619880008],[@bibr3-1076029619880008]^ However, these trials in immobilized hospitalized medical patients identified factors associated with an extended risk of VTE, such as advanced age, a past history of cancer or VTE, elevated [d]{.smallcaps}-dimer, or multiple medical comorbidities.^[@bibr3-1076029619880008],[@bibr6-1076029619880008]^

These risk factors were utilized to select the population included in the APEX trial.^[@bibr7-1076029619880008]^ In this study, extended thromboprophylaxis with betrixaban, a direct factor Xa inhibitor, reduced asymptomatic and symptomatic VTE events by up to 45% at the end of follow-up (day 77) compared with standard duration enoxaparin, without increasing major bleeding. This result was associated with reduction in symptomatic VTE including VTE-related hospitalizations, fatal and irreversible events, and reduction in ischemic strokes.^[@bibr8-1076029619880008][@bibr9-1076029619880008][@bibr10-1076029619880008]--[@bibr11-1076029619880008]^ Betrixaban is now approved in the United States for extended thromboprophylaxis in hospitalized acutely ill medical patients at extended risk for VTE. Using a US-wide data set of acute-care hospital medical patients, we estimated the annual number of patients at extended risk for VTE according to the selected APEX trial criteria.

Methods {#section2-1076029619880008}
=======

Annual estimates of the number of US hospitalized patients at risk of VTE according to 2012 American College of Chest Physicians (ACCP) guideline were derived from the 2014 US National Inpatient Sample (NIS), a data set available from the Healthcare Cost and Utilization Project (HCUP) sponsored by the US Agency for Healthcare Research and Quality (AHRQ).^[@bibr2-1076029619880008]^ The NIS data set includes all US states participating in HCUP, representing acute hospital care received by more than 95% of the US population.^[@bibr12-1076029619880008],[@bibr13-1076029619880008]^ The NIS databases are stratified probability samples of US community hospitals.^[@bibr12-1076029619880008]^ By definition, out-of-hospital events are not included.

Study Population {#section3-1076029619880008}
----------------

All inpatients aged ≥18 years who had a length of stay ≥2 days were included. Agency for Healthcare Research and Quality Clinical Classification System (CCS) codes were used to define the type of surgical procedure and the diagnosis of medical illness, as described in our previous publication.^[@bibr12-1076029619880008],[@bibr13-1076029619880008]^ Surgical patients were defined by inpatients who underwent a surgical procedure in an operating room. Primary procedure codes were used to characterize the type of surgery. According to the 2012 ACCP guideline, surgical patients with a Caprini score ≥3 (based mainly on the type of surgery and a length of stay ≥4 days as a surrogate for severe immobility) were considered at risk for VTE.^[@bibr14-1076029619880008]^ Surgical patients at no/low risk for VTE were reassessed according to their medical conditions and added to the medical population (inpatients who did not have a procedure in an operating room). For the purpose of our analysis, surgical patients at moderate, high, or highest risk for VTE were excluded.

Number of Patients at Extended Risk for VTE {#section4-1076029619880008}
-------------------------------------------

Major medical illnesses, included stroke, respiratory failure/chronic obstructive pulmonary disease, heart failure, pneumonia, other infections, and rheumatologic disorders (arthropathy/spondylopathy) placed hospitalized patients at risk for VTE. The 2 more common risk factors for VTE easily identified in the data set, namely age ≥75 years and a history of cancer (active and past) were considered. Indeed, other risk factors such as a history of VTE and elevated [d]{.smallcaps}-dimer are not comprehensively collected in the data set. Moreover, in keeping with the 2012 ACCP guideline based on the Padua Prediction Score risk assessment model which does not include inflammatory bowel disease as a risk factor for VTE, this medical condition was not included in our analysis.^[@bibr2-1076029619880008]^ Therefore, patients at extended risk for VTE were recognized by those aged ≥75 years or having a history of cancer (aged 40-74 years) admitted with a major medical illness. The first 3 CCS diagnostic codes were analyzed to determine the types of medical illness used for risk assessment. AHRQ definitions were used to identify comorbidities.

Outcomes {#section5-1076029619880008}
--------

Outcomes included the number and percent of medically ill patients at risk for posthospital discharge VTE, eligible for extended thromboprophylaxis.

Analyses {#section6-1076029619880008}
--------

All analyses were descriptive and were performed using SAS 9.4 (SAS Institute Inc, Cary, North Carolina). Categorical variables are reported as frequencies and percentages.

Results {#section7-1076029619880008}
=======

In 2014, an estimated 20.8 million adult medical patients with length of stay ≥2 days were discharged from US acute-care hospitals ([Figure 1](#fig1-1076029619880008){ref-type="fig"}). Respiratory failure (12%), heart failure (11%), and infections, classified as pneumonia and other infections (15%) were the commonest conditions ([Table 1](#table1-1076029619880008){ref-type="table"}). Overall, 7.2 million (35%) discharges presented with a major medical diagnosis associated with risk for VTE. Among them, 1.36 million patients had a history of cancer and 2.79 million were aged ≥75 years.

![Flow chart and estimated discharges at-risk for standard and extended duration thromboprophylaxis.](10.1177_1076029619880008-fig1){#fig1-1076029619880008}

###### 

Major Medical Illnesses Discharge Diagnoses in 2014 by Diagnosis, Age, and History of Cancer.

![](10.1177_1076029619880008-table1)

                                            Overall Discharges   Age Group in Year (n)   History of Cancer                                                                       
  ----------------------------------------- -------------------- ----------------------- ------------------- ------- ----------- ------- ----------- ------- ----------- ------- -----------
  Number (n)                                20 815 620           \% of All               5 684 465           27.3%   4 867 461   23.4%   4 902 047   23.5%   5 361 647   25.8%   
  Stroke                                    574 850              2.8%                    15 675              2.7%    118 960     20.7%   187 240     32.6%   252 975     44.0%   92 790
  Respiratory failure/COPD                  2 567 991            12.3%                   115 325             4.5%    592 080     23.1%   946 425     36.9%   914 160     25.6%   483 350
  Heart failure                             2 338 371            11.2%                   69 890              3.0%    413 485     17.7%   727 450     31.1%   1 127 546   48.2%   402 395
  Pneumonia                                 1 653 541            7.9%                    107 505             6.5%    344 915     20.9%   509 035     30.8%   692 085     41.9%   382 025
  Infections other than pneumonia           1 621 960            7.8%                    157 105             9.7%    390 595     24.1%   502 095     31.0%   572 165     35.2%   353 820
  Arthropathy/spondylopathy                 545 560              2.6%                    70 850              13.0%   187 495     33.8%   144 510     26.5%   142 705     26.2%   60 410
  Any of above                              7 209 343            34.6%                   457 865             6.4%    1 653 601   22.9%   2 306 431   32%     2 791 446   38.7%   1 365 111
  Age ≥75 or history of cancer (40-74)^a^   3 484 731            16.7%                   --                          207 895             485 390             2 791 446           1 336 801

Abbreviation: COPD, chronic obstructive pulmonary disease.

^a^ Limited APEX trial criteria (2 of the 4 main criteria for inclusion into the APEX study).

Discussion {#section8-1076029619880008}
==========

Our main finding was that among inpatients with medical conditions such as stroke, respiratory failure/chronic obstructive pulmonary disease, heart failure, pneumonia or other infections, or arthropathy/spondylopathy, almost half were either aged ≥75 years or aged 40 to 74 years with a history of cancer, representing 3.5 million patients of 7.2 million. These patients are considered to have an extended duration of high risk for VTE beyond the hospital stay. According to the APEX trial findings, these patients might benefit from thromboprophylaxis with betrixaban for up to 42 days, rather than standard duration thromboprophylaxis.

Current risk assessment tools, especially Padua Prediction Score mentioned in the ACCP guidelines, only identify patient at risk for VTE who require standard duration thromboprophylaxis but do not recognize high-risk patients who could benefit from extended prophylaxis.^[@bibr2-1076029619880008]^ Patients meeting the inclusion criteria of the APEX trial, namely hospitalized for major medical illness leading to severe immobility with advanced age (68% of the overall cohort), prior cancer (12%), prior VTE (8%), or elevated [d]{.smallcaps}-dimers, are at extended duration of high risk for VTE and benefit from extended thromboprophylaxis.

Age is recognized as an important risk factor for VTE in hospital and postdischarge, however significant 6-month frequencies of clinical VTE, around 4.5%, were seen in all age groups (\<65, 65-75, and \>75 years) in a recent US observational study.^[@bibr5-1076029619880008]^ Notably, in this study, most VTE occurred in outpatients and less than 10% of patients received post-discharge thromboprophylaxis. Another recent study has examined the population of US hospitalized medically ill patients who might qualify for extended thromboprophylaxis according to the modified IMPROVE score used in the MARINER study.^[@bibr15-1076029619880008]^ This score did not perform as well as expected by the trialists and identified a lower risk population resulting in an underpowering of the trial despite a 50% increase in the sample size. Rivaroxaban is undergoing regulatory approval for this indication. In comparison, in our study, the APEX criteria applied to the US hospitalized population recognized more patients. These patients were shown to be at high risk in the trial and betrixaban has Food and Drug Administration approval for this indication.

Our analysis estimates the potential clinical impact of extended thromboprophylaxis in hospitalized acutely ill medical patients on the reduction of VTE burden. Based on the APEX trial findings, and applied to our US data in 2014, extended thromboprophylaxis would have avoided 20 000 additional symptomatic VTE (number needed to treat \[NNT\] = 167), 15 000 all-cause strokes (NNT = 233), and 16 000 additional preventable deaths (NNT = 223) compared with current standard enoxaparin.^[@bibr7-1076029619880008],[@bibr8-1076029619880008],[@bibr10-1076029619880008],[@bibr11-1076029619880008]^ These data may serve as a basis to estimate the related economic impact of this strategy.^[@bibr16-1076029619880008]^

The major limitation was that the number of patients eligible for extended thromboprophylaxis described here is an overestimation and actually reflects a "maximum case scenario." Indeed, many reasons, including exclusion criteria from the APEX trial, especially risk factors for bleeding or polypharmacy with strong P-glycoprotein inhibitors, or costs, might preclude the actual prescription of extended betrixaban. Other limitations included that the extent of immobility was not captured in HCUP, thus our data potentially again overestimates the eligible population. Moreover, other known risk factors for VTE including 2 major risk factors recognized in the APEX trial, namely, prior VTE and [d]{.smallcaps}-dimer, were not comprehensively captured in the data set which would on the contrary underestimate the extended risk population by 10% to 15%. Finally, the data set does not collect data on medication utilization. Therefore, our study was not able to estimate neither the proportion of at-risk patients who received thromboprophylaxis nor whether antithrombotic therapies, when used, were given appropriately.

Conclusion {#section9-1076029619880008}
==========

Based on this "maximum case scenario," almost half of the high-risk hospitalized acutely ill medical patients currently eligible for standard duration thromboprophylaxis are at extended risk and might benefit from the awareness of continuing risk. Some of these patients might benefit from extended thromboprophylaxis, depending on the risk of bleeding and comorbidities.
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